We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Curis and Debiopharm Announce Initiation of Phase I-II Clinical Study of HSP90 Inhibitor
News

Curis and Debiopharm Announce Initiation of Phase I-II Clinical Study of HSP90 Inhibitor

Curis and Debiopharm Announce Initiation of Phase I-II Clinical Study of HSP90 Inhibitor
News

Curis and Debiopharm Announce Initiation of Phase I-II Clinical Study of HSP90 Inhibitor

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Curis and Debiopharm Announce Initiation of Phase I-II Clinical Study of HSP90 Inhibitor"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Curis, Inc. and Debiopharm Group™ have announced that Debiopharm has begun treating patients in its HALO Phase I/II clinical trial of orally-administered Heat Shock Protein 90 (HSP90) inhibitor Debio 0932 in combination with chemotherapy regimens in patients with advanced stages of non-small cell lung cancer (NSCLC).

“Our team is pleased to report that we have successfully advanced Debio 0932 into a large clinical trial to study its potential to provide benefit to patients suffering from non-small cell lung cancer”, said Rolland-Yves Mauvernay, President and Founder of Debiopharm Group, who added: “We believe that HSP90 represents an important molecular target in cancer therapy in general and in lung cancer in particular. We expect this Phase I-II study as well as the ongoing Phase Ib clinical trial to yield key data that will guide this important molecule’s further development”.

“Debiopharm has generated a body of clinical data with Debio 0932 to date, showing that it is generally well tolerated and that the molecule demonstrates signs of clinical activity, including a confirmed partial response that was observed in a patient with K-ras-mutated lung cancer”, said Dan Passeri, Curis’ President and Chief Executive Officer.

Passeri continued, “We believe that these data demonstrate the potential of Debio 0932 and our HSP90 inhibitor technology, and importantly, Curis is eligible for future milestone payments based on the successful achievement of specific clinical development and regulatory approval objectives under this collaboration”.

Advertisement